趋化因子配体13在常见感染性病原体感染中的表达及意义

doi:10.19871/j.cnki.xfcrbzz.2023.05.015

摘要/Abstract

摘要： 趋化因子配体13（C-X-C motif chemokine ligand 13,CXCL13）又称B细胞吸引趋化因子1或B淋巴细胞趋化因子,通过与B细胞、辅助T细胞上的G蛋白偶联趋化因子受体结合,诱导其向生发中心运输,促进B细胞成熟和抗体应答,从而实现对病毒清除以及炎症的快速控制。然而,目前相关研究表明CXCL13水平过高可能导致免疫反应受损,促进疾病进展。CXCL13水平变化可作为反映疾病进展、抗病毒疗效有效指标,并且对疫苗研发有所帮助。因此,本文主要对CXCL13在常见感染性病原体感染如人类免疫缺陷病毒感染、乙型肝炎病毒感染、结核分枝杆菌感染以及SARS-CoV-2感染中的表达及其意义进行综述。

关键词: 趋化因子配体13, 人类免疫缺陷病毒, 乙型肝炎病毒, 结核分枝杆菌

Abstract: C-X-C motif chemokine ligand 13 (CXCI13) can promote B cell maturation and antibody response by binding to G protein-coupled chemokine receptor (CXCR5) that locating on B cells and Tfh cells.Consequently,the inhibition of virus replication, even the elimination of virus,can be realized,which conclusively facilitating to the rapid control of inflammation.However,it should be noted that excessive increase of CXCL13 may lead to impaired immune response and further deterioration of infection. In view of these important effects, the change of CXCL13 concentration is likely to become an effective index for evaluation of disease progression and antiviral efficacy, and will be helpful for future vaccine development. In summary, the paper mainly reviews the expression and significance of CXCL13 in common infectious pathogens such as human immunodeficiency virus, hepatitis B virus infection, tuberculosis and SARS-CoV-2.

Key words: C-X-C motif chemokine ligand 13, Human immunodeficiency virus, Hepatitis B virus, Mycobacterium tuberculosis

中图分类号:

R51
R446.1

陈芝慧, 谭英征, 龙云铸. 趋化因子配体13在常见感染性病原体感染中的表达及意义[J]. 新发传染病电子杂志, 2023, 8(5): 80-84.

Chen Zhihui, Tan Yingzheng, Long Yunzhu. Expression and significance of C-X-C motif chemokine ligand 13 in common infectious pathogens infection[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(5): 80-84.

参考文献

[1] KAZANIETZ MG, DURANDO M, COOKE M.CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond[J]. Front Endocrinol, 2019, 10: 471.
[2] SHI K, HAYASHIDA K, KANEKO M, et al.Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients[J]. J Immunol, 2001, 166(1): 650-655.
[3] DAVID BA, KUBES P.Exploring the complex role of chemokines and chemoattractants in vivo on leukocyte dynamics[J]. Immunol Rev, 2019, 289(1): 9-30.
[4] BEKELE FY, CHIODI F, SUI Y, et al.The Role of CXCL13 in Antibody Responses to HIV-1 Infection and Vaccination[J]. Front Immunol, 2021, 12: 638872.
[5] WANG B, WANG M, AO D, et al.CXCL13-CXCR5 axis: Regulation in inflammatory diseases and cancer[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(5): 188799.
[6] CARLSEN HS, BAEKKEVOLD ES, MORTON HC, et al.Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis[J]. Blood, 2004, 104(10): 3021-3027.
[7] SCHAERLI P, LOETSCHER P, MOSER B.Cutting edge: induction of follicular homing precedes effector Th cell development[J]. J Immunol, 2001, 167(11): 6082-6086.
[8] HAVENAR-DAUGHTON C, LINDQVIST M, HEIT A, et al.CXCL13 is a plasma biomarker of germinal center activity[J]. Proc Natl Acad Sci U S A, 2016, 113(10): 2702-2707.
[9] DUAN Z, GAO J, ZHANG L, et al.Phenotype and function of CXCR5+CD45RA-CD4+T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis[J]. Oncotarget, 2015, 6(42): 44239-44253.
[10] LEE JH, CROTTY S.HIV vaccinology: 2021 update[J]. Semin Immunol, 2021, 51: 101470.
[11] VIDYA VIJAYAN KK, KARTHIGEYAN KP, TRIPATHI SP, et al.Pathophysiology of CD4+T-Cell Depletion in HIV-1 and HIV-2 Infections[J]. Front Immunol, 2017, 8: 580.
[12] CROTTY S.T Follicular Helper Cell Biology: A Decade of Discovery and Diseases[J]. Immunity, 2019, 50(5): 1132-1148.
[13] KAW S, ANANTH S, TSOPOULIDIS N, et al.HIV-1 infection of CD4 T cells impairs antigen-specific B cell function[J]. EMBO J , 2020, 39(24): e105594.
[14] OLATUNDE AC, HALE JS, LAMB TJ.Cytokine-skewed Tfh cells: functional consequences for B cell help[J]. Trends Immunol, 2021, 42(6): 536-550.
[15] CAGIGI A, MOWAFI F, PHUONG DANG LV, et al.Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection[J]. Blood, 2008, 112(12): 4401-4410.
[16] WIDNEY DP, BREEN EC, BOSCARDIN WJ, et al.Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection[J]. J Interferon Cytokine Res, 2005, 25(11): 702-706.
[17] BARONE F, BOMBARDIERI M, ROSADO MM, et al.CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization[J]. J Immunol, 2008, 180(7): 5130-5140.
[18] LINDQVIST M, VAN LUNZEN J, SOGHOIAN DZ, et al.Expansion of HIV-specific T follicular helper cells in chronic HIV infection[J]. J Clin Invest, 2012, 122(9): 3271-3280.
[19] MEHRAJ V, RAMENDRA R, ISNARD S, et al.CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection[J]. Front immunol, 2019, 10: 289.
[20] SOK D, LASERSON U, LASERSON J, et al.The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies[J]. PLoS Pathog, 2013, 9(11): e1003754.
[21] KLEIN F, DISKIN R, SCHEID JF, et al.Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization[J]. Cell, 2013, 153(1): 126-138.
[22] COHEN K, ALTFELD M, ALTER G, et al.Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection[J]. J Virol, 2014, 88(22): 13310-13321.
[23] ABELA IA, KADELKA C, TRKOLA A.Correlates of broadly neutralizing antibody development[J]. Curr Opin HIV AIDS, 2019, 14(4): 279-285.
[24] BURTON DR, AHMED R, BAROUCH DH, et al.A Blueprint for HIV Vaccine Discovery[J]. Cell Host Microbe, 2012, 12(4): 396-407.
[25] MABUKA JM, DUGAST AS, MUEMA DM, et al.Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies[J]. Front Immunol, 2017, 8: 1104.
[26] GUO AL, JIAO YM, ZHAO QW, et al.Implications of the accumulation of CXCR5(+) NK cells in lymph nodes of HIV-1 infected patients[J]. EBio Medicine, 2022, 75: 103794.
[27] ZEISEL MB, LUCIFORA J, MASON WS, et al.Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure[J]. Gut, 2015, 64(8): 1314-1326.
[28] DURANTEL D, ZOULIM F.New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus[J]. J Hepatol, 2016, 64(1): 117-131.
[29] 中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019, 35(8): 1693-1701.
[30] PUBLICOVER J, GAGGAR A, NISHIMURA S, et al.Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B[J]. J Clin Invest, 2013, 123(9): 3728-3739.
[31] ANSEL KM, NGO VN, HYMAN PL, et al.A chemokine-driven positive feedback loop organizes lymphoid follicles[J]. Nature, 2000, 406(6793): 309-314.
[32] LIU C, HUANG X, WERNER M, et al.Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy[J]. Front Immunol, 2017, 8: 323.
[33] FENG J, LU L, HUA C, et al.High frequency of CD4+ CXCR5+ TFH cells in patients with immune-active chronic hepatitis B[J]. PloS one, 2011, 6(7): e21698.
[34] YOSHIO S, MANO Y, DOI H, et al. Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients [J]. JCI insight, 2018, 3(20) :e122268.
[35] LI Y, TANG L, GUO L, et al.CXCL13-mediated recruitment of intrahepatic CXCR5(+)CD8(+) T cells favors viral control in chronic HBV infection[J]. J Hepatol, 2020, 72(3): 420-430.
[36] LI Y, WANG W, TANG L, et al.Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis[J]. Hepatology, 2015, 61(6): 1998-2007.
[37] LI Y, MA S, TANG L, et al.Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection[J]. Hepatology, 2013, 58(4): 1277-1286.
[38] WAN Z, LIN X, LI T, et al.Genetic variant in CXCL13 gene is associated with susceptibility to intrauterine infection of hepatitis B virus[J]. Sci Rep, 2016, 6: 26465.
[39] 宋敏,陆普选,方伟军,等. 2022年WHO全球结核病报告:全球与中国关键数据分析[J/CD].新发传染病电子杂志,2023, 8(1):87-92.
[40] NATARAJAN A, BEENA PM, DEVNIKAR AV, et al.A systemic review on tuberculosis[J]. Indian J Tuberc, 2020, 67(3): 295-311.
[41] DEPIANTO DJ, CHANDRIANI S, ABBAS AR, et al.Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis[J]. Thorax, 2015, 70(1): 48-56.
[42] IGNACIO A, BREDA CNS, CAMARA NOS.Innate lymphoid cells in tissue homeostasis and diseases[J]. World J Hepatol, 2017, 9(23): 979-989.
[43] PANDA SK, COLONNA M.Innate Lymphoid Cells in Mucosal Immunity[J]. Front Immunol, 2019, 10: 861.
[44] EBERL G, COLONNA M, DI SANTO JP, et al. Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology [J]. Science, 2015, 348(6237): aaa6566.
[45] COLONNA M.Innate Lymphoid Cells: Diversity, Plasticity, and Unique Functions in Immunity[J]. Immunity, 2018, 48(6): 1104-1117.
[46] NARINYAN W, POLADIAN N, ORUJYAN D, et al.Immunologic Role of Innate Lymphoid Cells against Mycobacterial tuberculosis Infection[J]. Biomedicines, 2022, 10(11):2828.
[47] ARDAIN A, DOMINGO-GONZALEZ R, DAS S, et al.Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis[J]. Nature, 2019, 570(7762): 528-532.
[48] ZENG B, XING R, DONG C, et al.Commentary: Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis[J]. Front Immunol, 2020, 11: 1925.
[49] SLIGHT SR, RANGEL-MORENO J, GOPAL R, et al.CXCR5 T helper cells mediate protective immunity against tuberculosis[J]. J Clin Invest, 2013, 123(2): 712-726.
[50] JIANG J, CAO Z, QU J, et al.PD-1-expressing MAIT cells from patients with tuberculosis exhibit elevated production of CXCL13[J]. Scand J Immunol, 2020, 91(4): e12858.
[51] AZKUR AK, AKDIS M, AZKUR D, et al.Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19[J]. Allergy, 2020, 75(7): 1564-1581.
[52] 廖康生,卢洪洲. 新型冠状病毒奥密克戎变异株的研究进展:对其科学防控措施的启示[J/CD].新发传染病电子杂志,2022, 7(1):1-5.
[53] WU Z, MCGOOGAN JM.Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention[J]. Jama, 2020, 323(13): 1239-1242.
[54] MEHTA P, MCAULEY DF, BROWN M, et al.COVID-19: consider cytokine storm syndromes and immunosuppression[J]. Lancet, 2020, 395(10229): 1033-1034.
[55] CATANZARO M, FAGIANI F, RACCHI M, et al.Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2[J]. Signal Transduct Target Ther, 2020, 5(1): 84.
[56] LEISMAN DE, RONNER L, PINOTTI R, et al.Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes[J]. Lancet Respir Med, 2020, 8(12): 1233-1244.
[57] WONG CK, LAM CW, WU AK, et al.Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome[J]. Clin Exp Immunol, 2004, 136(1): 95-103.
[58] HORSPOOL AM, KIEFFER T, RUSS BP, et al.Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel Biomarker of Lethal SARS-CoV-2 Infection[J]. mSphere, 2021, 6(1): e01324-e01420.
[59] PERREAU M, SUFFIOTTI M, MARQUES VP, et al.The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients[J]. Nat Commun, 2021, 12(1):4888.
[60] JONES JD, HAMILTON BJ, CHALLENER GJ, et al.Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels[J]. Arthritis Res Ther, 2014, 16(2): R103.
[61] TRAIANOS EY, LOCKE J, LENDREM D, et al.Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren's syndrome[J]. Rheumatol Int, 2020, 40(4): 541-548.
[62] FINCH DK, ETTINGER R, KARNELL JL, et al.Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease[J]. Eur J Clin Invest, 2013, 43(5): 501-509.